27.07.2011 • News

Merck KGaA Slips To Loss In Q2; Trims FY11 Profit Forecast

German drug manufacturer Merck KGaA reported Wednesday that its second-quarter net loss attributable to the company was €85.9 million or €0.40 per share, compared to prior year's profit of €183.4 million or €0.84 per share.

Core earnings per share, which excluded certain one-time items, declined 39.7% to €0.94 from €1.56 last year.

Total revenues increased 15.7% to €2.56 billion from €2.21 billion a year ago.

For the quarter, core operating result declined from last year, while underlying core operating result grew to €548 million from €501 million in 2010.

Looking ahead for fiscal 2011, the company now projects total revenues will increase to between €10 billion and €10.4 billion. The group operating result for 2011 is expected to amount to about €1 billion, which is below the guidance given in April primarily due to the many one-time adjustments.
The company's previous forecast for total revenues was a growth of 10 -15%.

 

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read